PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

American Medical Association CEO calls laws banning kids trans surgeries ‘dangerous governmental intrusion’

Show Me

Uganda Detects Covid-19 Variant From India, Urges Caution

Show Me

Dr. John Eastman to Hold Press Conference Thursday at Noon MDT – After Being Fired for Speaking at a Trump Rally

Show Me

Massachusetts Man Took Over ‘OG’ Social Media Accounts to Steal Cryptocurrency: Justice Department

Show Me

Trump defends ‘great patriot’ Rudy Giuliani after ‘unfair’ FBI raid

Show Me

No, Other People’s Covid Vaccines Can’t Disrupt Your Menstrual Cycle

Show Me

High School Runner About To Set Record Collapses At Finish, Blames Outdoor Mask Mandate

Show Me

Joy Behar Claims Tim Scott ‘Doesn’t Understand’ The Difference Between A Racist Country And Systemic Racism

Show Me

Kamala Harris: America Isn’t a Racist Country — But We Have to ‘Speak Truth’ About History of Racism

Show Me

‘The 1619 Project’ and the Red Meat Project

Show Me

Caught on camera: Liz Cheney fist-bumps Biden before his speech

Show Me

Hawley Introduces Bill to Reduce Pentagon’s Reliance on Technology from China and Other ‘Adversary Nations’

Show Me

Water: The Forgotten Nutrient

Show Me

April 29, 2021 | Nightly News Rebroadcast | Video: 52 Minutes 29 Seconds

Show Me

German spies monitor anti-lockdown activists for suspected sedition

Show Me

Purchase Orders Show FDA Bought “Fresh” Livers of Viable Babies Killed in Abortions

Show Me

NC Sheriff: 2 deputies killed, suspect and 2 others dead

Show Me

Trump Floats 2024 Presidential Run Again, Says DeSantis Could Be Potential Running Mate

Show Me

Ashli Babbitt’s family plans to sue Capitol Police, officer who shot her

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded April 29, 2021 | Video: 48 Minutes 19 Seconds

Show Me

Giuliani’s Lawyer Accuses DOJ of ‘Corrupt Double Standard’ In Executing Warrants Against Him

Show Me

US Catholic bishops may press Biden to stop taking Communion

Show Me

WATCH: Christian Pastor Arrested in London for Quoting ‘Homophobic’ Bible Verses

Show Me

Minneapolis parking app hacked, personal information stolen

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded April 29, 2021 | Video: 47 Minutes 58 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded April 29, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Scott Outshines Biden, Enrages Libs With Inspiring Tale of Overcoming Adversity

Show Me

CCP Arrests Netizen for Posting Vaccine Death

Show Me

Facebook Blocks #ResignModi Posts for Hours as India Crisis Grows

Show Me

Border Patrol Chief Tells Biden: ‘I Cannot’ Comply With Demand To Use Non-Legal Immigration Terms

Show Me

U.S. Tells Citizens to Leave India as Covid-19 Swamps Hospitals

Show Me

Pompeo knocks Biden: He ‘successfully outlined a radical, socialist agenda’

Show Me

Biden Takes Credit for Ending Afghan War – After Extending It – in Speech to Congress

Show Me

Judge Denies Request to Stop Arizona Audit | Recorded April 28, 2021 | Video: 12 Minutes 44 Seconds

Show Me

Pompeo: Trump Changed How We Look at China | Americans’ Distrust in Media at Record High

Show Me

April 28, 2021 | Nightly News Rebroadcast | Video: 52 Minutes 29 Seconds

Show Me

Connecticut Lawmakers Vote to Repeal Religious Exemptions to Vaccines, Health Freedom Advocates Vow Legal Challenge

Show Me

Texas Counties Declare Disaster Over Border Crisis

Show Me

Ex-Trump aide sues Biden administration, alleging discrimination against white farmers

Show Me

Astronaut Michael Collins, Apollo 11 pilot, dead of cancer

Show Me